The Australian Technical Advisory Group on Immunisation (ATAGI) has released clinical guidance on the use of a different COVID-19 vaccine as the second dose.

The advice recommends to use the same COVID-19 vaccine for the 2 doses of the primary vaccination course, unless there are specific medical reasons not to do so, or the same vaccine brand is not available in Australia.

The ATAGI advice explains:
• The medical contraindications and serious vaccine-attributable adverse events after
dose 1 of a COVID-19 vaccine that warrant using an alternative vaccine brand for dose 2
• The medical conditions that mean that Comirnaty is recommended over COVID-19
Vaccine AstraZeneca
• The recommendations for completing the primary vaccination course for people who
have received dose 1 with a vaccine that is not available in Australia.

To read the statement in full, please click the link below:
ATAGI statement: ATAGI clinical advice on use of a different COVID-19 vaccine as the second dose in special circumstances

For further information on COVID-19 mixed vaccine schedules refer to MVEC: COVID-19 mixed vaccine schedules. 

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个